PTJ
SGTX

Paul Tudor Jones’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Paul Tudor Jones’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-592
Closed -$370K – 1934
2020
Q4 		$370K Buy
+592
New +$269K 0.01% 1052

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paul Tudor Jones's SGTX Position: Q1 2021 in Review

Paul Tudor Jones sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2021, closing a stake of 592 shares — an estimated $370K sold.

Paul Tudor Jones first reported a position in SGTX in Q4 2020 and held it in 1 quarter. The position peaked at $370K in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q1 2021.

  • Paul Tudor Jones reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 592 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $370K.
  • Paul Tudor Jones first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Paul Tudor Jones's Sigilon Therapeutics, Inc. Common Stock position peaked at $370K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Tudor Investment Corp's 13F filing for Q1 2021, filed 17 May 2021.